


THE OASIS PHASE 2 STUDY

ETRASIMOD* IN ULCERATIVE COLITIS (UC)

OASIS PHASE 2


A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study

Etrasimod is an investigational, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator designed to selectively target receptors 1, 4, and 5.




QD: once daily.

TRIAL INFORMATION



Patients received oral **etrasimod** 1 mg or 2 mg or placebo once daily for 12 weeks



Conducted at 87 centers in 17 countries with 156 patients



Evaluated the **efficacy and safety of etrasimod** (1 mg and 2 mg) in patients with **moderately to severely active UC**

ENDPOINTS EVALUATED

PRIMARY

Improvement of modified Mayo Clinic Score (mMCS) at Week 12

SECONDARY

- Proportion of patients who achieved endoscopic improvement (ES=0/1) at Week 12
- Improvement in 2-component MCS (SF + RB) at Week 12
- Improvement in Total Mayo Clinic Score at Week 12

SELECTED EXPLORATORY

Proportion of patients who achieved:

- Clinical remission at Week 12
- Clinical response at Week 12
- Histologic improvement and remission

ES: endoscopic subscore; RB: rectal bleeding; SF: stool frequency.

2-component MCS (score ranging from 0 to 6, including rectal bleeding and findings on endoscopy).


mMCS (score ranging from 0 to 9, including stool frequency, rectal bleeding, and findings on endoscopy).

Total Mayo Clinic Score (score ranging from 0 to 12, including stool frequency, rectal bleeding, findings on endoscopy, and physician's global assessment).

LEARN MORE ABOUT THE OASIS TRIAL

SEE THE FOLLOWING PUBLICATIONS:

Sandborn et al. *Gastroenterology*. 2020;158(3):550-561



Vermeire et al. *J Crohns Colitis*. 2021. doi:10.1093/ecco-jcc/jjab016



Arena has advanced **etrasimod** into the Phase 3 ELEVATE clinical development program.

*Etrasimod is an investigational drug and is not currently approved for use by any health authority.

References:

1. Sandborn. doi:10.1053/j.gastro.2019.10.035
2. Vermeire. doi:10.1093/ecco-jcc/jjab016
3. Clinicaltrials.gov: NCT02447302, NCT02536404
4. Chiorean. doi:10.14309/01.ajg.0000705120.52073.1b